Bücher von Imran Chaki

A simple, rapid, accurate, sensitive, precise, and isocratic RP- HPLC method was develop for analysis of Nebivolol Hydrochloride and Indapamide in combined tablet dosage form. The best separation was achieved by C-18 reversed phase column (250 mm x 4.6 mm, 5¿m particle) with 50 mM Potassium dihydrogen phosphate, pH 3.5 adjusted with ortho phosphoric acid, acetonitrile and triethylamine in ratio (30:70:2 v/v) as mobile phase. Flow rate was set 1 ml/min and detection was carried out at 254 nm. Retention time of Nebivolol Hydrochloride and Indapamide was found to be 3.407 min. and 5.470 min. respectively. The Method has been validated for the combination with parameters like linearity, accuracy and precision and rubustness. Linear response for Nebivolol Hydrochloride and Indapamide were in the range of 50-150 ¿g/ml and 15-45 ¿g/ml respectively. The Percentage recoveries obtained for Nebivolol Hydrochloride and Indapamide were found to be 99.87 ± 0.20 and 99.93 ± 0.187 respectively. The study further extended to develop stability indicating method where acid, base, oxidation and thermal degradation was performed.

The present work describes various methods for the simultaneous estimation of Diclofenac sodium (DICLO) and Pantoprazole (PANTO) in combined Capsule dosage form. A simple, accurate and reproducible RP-HPLC method have been developed and validated for the simultaneous estimation of Diclofenac sodium and Pantoprazole in their marketed formulation. The RP-HPLC methods were validated by Stastically. The retention times of Diclofenac sodium and Pantoprazole were found to be 3.33 ± 0.10 min and 6.66 ± 0.10 min, respectively. Linearity was evaluated over the concentration range of 18.75-56.25 µg/ml for DICLO and 5-15 µg/ml for PANTO by RP-HPLC method. The correlation coefficient and accuracy of both the methods were found to be within the range. The % RSD of precision was found to be NMT 2.0 % for HPLC method. The proposed methods were found to be robust when slight but deliberate changes were made in analytical conditions. Simple, accurate and reproducible RP-HPLC method were developed and validated for the simultaneous estimation of Diclofenac sodium and Pantoprazole in their marketed formulation. The proposed methods can be applied for the routine analysis in quality control laboratory.

Cefixime Trihydrate and Moxifloxacin Hydrochloride combination was given approval by Central Drug Standard Control Organization (CDSCO) on 8th August 2011. There are very few methods have been reported for simultaneous estimation of Cefixime Trihydrate and Moxifloxacin Hydrochloride. Spectrophotometric methods (Q-Absorption Method and First Derivative Method) and RP- HPLC method were developed and validated for simultaneous estimation of Cefixime Trihydrate and Moxifloxacin Hydrochloride in combined dosage form. Analysis was carried using two methods - spectrophotometric method and RP-HPLC method. The developed methods were simple, rapid, precise,and accurate and so it can be successfully used for the simultaneous estimation in quality control laboratory.

Development and validation of simple, precise, accurate, economical and sensitive HPLC assay method for the estimation of Cefixime and Linezolid in tablet dosage form. A chromatographic separation was achieved with a Hypersil BDS C18 (250mm,4.6mm ,5µm) analytical column. A Mixture of Phosphate Buffer (3.0 pH): methanol (40:60, v/v) was used as the mobile phase, at a flow rate of 1.0 ml/min and detector wavelength at 277 nm. The retention time of Cefixime and linezolid was found to be 3.76 and 6.55 min respectively. Theoretical plates was 6896 and 4626 respectively and Tailing factor was 1.32 and 1.28. The linear ranges was 5-15 for cefixime and 15-45 ¿g/ml for linezolid, and the correlation coefficient was 0.999 for both drugs. The relative standard deviation was found to be less than 2%. A simple, precise, accurate, economical and sensitive HPLC assay method have been developed and validated for the estimation of Cefixime and linezolid in tablet dosage form. All method validation parameters lie within its acceptance crieteria as per ICH Q2(R1) guideline.